BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35943677)

  • 21. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 22. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
    Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
    Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1.
    Yakymiv Y; Augeri S; Bracci C; Marchisio S; Aydin S; D'Ardia S; Massaia M; Ferrero E; Ortolan E; Funaro A
    Sci Rep; 2021 Oct; 11(1):21230. PubMed ID: 34707185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.
    Lin KH; Winter PS; Xie A; Roth C; Martz CA; Stein EM; Anderson GR; Tingley JP; Wood KC
    Sci Rep; 2016 Jun; 6():27696. PubMed ID: 27283158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a
    Liu T; Lam V; Thieme E; Sun D; Wang X; Xu F; Wang L; Danilova OV; Xia Z; Tyner JW; Kurtz SE; Danilov AV
    Clin Cancer Res; 2021 Sep; 27(17):4910-4922. PubMed ID: 34233959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
    Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
    Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation.
    Wang CC; Liu HE; Lee YL; Huang YW; Chen YJ; Liou JP; Huang HM
    Tumour Biol; 2016 May; 37(5):6065-72. PubMed ID: 26608370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.
    Lu F; Zhang J; Ji M; Li P; Du Y; Wang H; Zang S; Ma D; Sun X; Ji C
    Int J Oncol; 2014 Jul; 45(1):383-92. PubMed ID: 24756163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.
    Jin L; Tabe Y; Kojima K; Shikami M; Benito J; Ruvolo V; Wang RY; McQueen T; Ciurea SO; Miida T; Andreeff M; Konopleva M
    J Mol Med (Berl); 2013 Dec; 91(12):1383-97. PubMed ID: 23955073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
    Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
    Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
    Clin Cancer Res; 2016 Mar; 22(5):1211-21. PubMed ID: 26459180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.
    Kaufmann SH; Karp JE; Svingen PA; Krajewski S; Burke PJ; Gore SD; Reed JC
    Blood; 1998 Feb; 91(3):991-1000. PubMed ID: 9446661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
    Li X; Su Y; Hege K; Madlambayan G; Edwards H; Knight T; Polin L; Kushner J; Dzinic SH; White K; Yang J; Miller R; Wang G; Zhao L; Wang Y; Lin H; Taub JW; Ge Y
    Haematologica; 2021 May; 106(5):1262-1277. PubMed ID: 32165486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
    Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
    Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Luedtke DA; Niu X; Pan Y; Zhao J; Liu S; Edwards H; Chen K; Lin H; Taub JW; Ge Y
    Signal Transduct Target Ther; 2017; 2():17012. PubMed ID: 29263915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis.
    Liu Y; Lei P; Qiao H; Sun K; Lu X; Bao F; Yu R; Lian C; Li Y; Chen W; Xue F
    Int J Biol Sci; 2019; 15(3):579-586. PubMed ID: 30745844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. All-trans retinoic acid enhanced the antileukemic efficacy of ABT-199 in acute myeloid leukemia by downregulating the expression of S100A8.
    Li D; Li H; Cheng C; Li G; Yuan F; Mi R; Wang X; Li D; Fan R; Wei X
    Int Immunopharmacol; 2022 Nov; 112():109182. PubMed ID: 36058034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.
    Carter BZ; Mak PY; Tao W; Zhang Q; Ruvolo V; Kuruvilla VM; Wang X; Mak DH; Battula VL; Konopleva M; Jabbour EJ; Hughes PE; Chen X; Morrow PK; Andreeff M
    Mol Cancer Ther; 2022 Jun; 21(6):879-889. PubMed ID: 35364607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.
    Niu X; Zhao J; Ma J; Xie C; Edwards H; Wang G; Caldwell JT; Xiang S; Zhang X; Chu R; Wang ZJ; Lin H; Taub JW; Ge Y
    Clin Cancer Res; 2016 Sep; 22(17):4440-51. PubMed ID: 27103402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.